Drug discovery company STORM Therapeutics reported on Friday that it has raised another GBP14m to bring the total Series A financing to GBP30m.
The new financing includes the new investor, Seroba Life Sciences as well as existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group.
According to STORM, it will use the funds to advance its broad pipeline in preclinical development, accelerate its programmes towards the clinic as well as support its growth as the leading RNA modulating enzymes drug discovery company.
In addition, STORM has named Dr Mark Albertella as VP Translational Oncology. Mark was previously Director of Biology at Medivir AB as well as part of Argenta, OSI Pharmaceuticals, Kudos and AstraZeneca.
On 21 May, STORM Therapeutics' CEO Keith Blundy will give a presenatation at the BioEquity Europe 2019 meeting in Barcelona at 9:00 CEST.
(USD1=GBP0.784529)
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis